GDC-0449 in patients with advanced chondrosarcomas: a French Sarcoma Group/US and French National Cancer Institute Single-Arm Phase II Collaborative Study - Italiano, A.; Le Cesne, A.; Bellera, C.; Piperno-Neumann, S.; Duffaud, F.; Penel, N.; Cassier, P.; Domont, J.; Takebe, N.; Kind, M.; Coindre, J.-M.; Blay, J.-Y.; et al. (Annals of oncology, 2013)
Keywords: Adult; Aged; Aged, 80 and over; Anilides - administration & dosage; Antineoplastic agents; Biological and medical sciences; chondrosarcoma; Chondrosarcoma - drug therapy; Chondrosarcoma - genetics; Chondrosarcoma - pathology; Disease-Free Survival; Diseases of the osteoarticular system; Drug-Related Side Effects and Adverse Reactions - classification; Drug-Related Side Effects and Adverse Reactions - pathology; Female; France; GDC-0449; Gene Expression Regulation, Neoplastic; Hedgehog pathway; Hedgehog Proteins - biosynthesis; Hedgehog Proteins - genetics; Humans; Male; Medical sciences; Middle Aged; Original; Pharmacology. Drug treatments; Pyridines - administration & dosage; treatment; Tumors of striated muscle and skeleton; France; GDC-0449; chondrosarcoma; treatment; Hedgehog pathway; Human; Chondrosarcoma; Sarcoma; Toxicity; Diseases of the osteoarticular system; Malignant tumor; Cartilage; Treatment; Hedgehog protein; Phase II trial; Advanced stage; Inhibitor; Cancer